QLI: Qilian International Holding Group Limited Price-to-Revenue Coefficient
Qilian International operations are restricted by strict FDA medical regulations regarding the disposal of biomaterials. The price-to-sales trend clearly demonstrates the business's resilience to shocks, with the indicator reaching 4.20. The growth of biologics is driven by synergy with Chinese agricultural holdings, although trade wars with the US create risks of Western capital blockages and more stringent quality audits.
Metric breakdowns and analytics for Qilian International Holding Group Limited (QLI)
- market value and analyst target forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Qilian International|QLI - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Qilian International Corp|QLI - Company Total Debt|Debt to Net Assets Ratio Qilian International Holding Group Limited|QLI - Company Long-Term Debts|Short-Term Debt Volume Qilian International|Immediate Liquidity Ratio qlsyy.net
- financial results and valuation multiples details:
QLI - Net Income|Future Net Profit Qilian International|QLI - P/E Multiple|Projected Price to Earnings Ratio Qilian International Holding Group|QLI - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Qilian International Holding Group Limited|QLI - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Qilian International|QLI - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth qlsyy.net|QLI - Net earnings per share growth this year|Projected earnings per share increase next year Qilian International
- issuer revenue and sales details:
Summary company analytics:qlsyy.net, QLI
The price-to-sales ratio dynamics for Qilian International (QLI) on the GURU.Markets platform reflect the impact of drug portfolio diversification and raw material supply stability on the business's market valuation. This multiple, calculated as the ratio of market capitalization to annual revenue, determines whether the asset is overvalued or if the capital is undervalued relative to the company's actual operational cash flows.
Competing companies
haleon.com (HLN) - Price-to-Revenue Multiple|P/S Multiple KVUE (Kenvue)|Price-to-Revenue Coefficient Verona Pharma PLC (VRNA)|MENS - Price-to-Revenue Ratio|LGND: Price-to-Revenue Ratio|AMRX: P/S Multiple|PRGO - Price-to-Revenue Coefficient|ALVO (Alvotech SA) - P/S Multiple|P/S Multiple Liquidia Corp|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANI Pharmaceuticals Corp - Market Cap to Revenue Ratio|MannKind Corporation - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio AMPH|Pacira BioSciences, Inc. - P/S Multiple|Price-to-Revenue Coefficient ARS Pharmaceuticals Inc SPRY|Theravance (TBPH) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio AQST|Market Cap to Revenue SCPH|TECX (Tectonic) - Market Cap to Sales Volume|P/S Multiple TNXP|SXTC - Price to Sales|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|Market Capitalization-to-Revenue Ratio BHST|EXOZ - Price-to-Revenue Ratio|ORMP (Oramed Pharmaceuticals) - Market Cap to Revenue Ratio|ENTX: P/S Multiple|MindWalk Holdings, Inc. (HYFT) - P/S Multiple|Market Cap to Revenue ABVC|CPIX (Cumberland Corp) - Market Cap to Sales Volume|P/S Multiple QNTM|Price-to-Revenue Coefficient fibrogen.com|Price-to-Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings (RANI) - Price to Sales|SNYR - Price-to-Revenue Ratio|RLYB (Rallybio Corporation) - Market Cap to Revenue Ratio|LEXX: P/S Multiple|pulmatrix.com (PULM) - P/S Multiple|Price-to-Revenue Ratio Pheton Holdings Limited|Price-to-Revenue Ratio APM|Price-to-Revenue Ratio Lyra Therapeutics, Inc (LYRA)|Impact BioMedical, Inc. (IBO) - Price-to-Revenue Multiple|Price-to-Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Price-to-Revenue Ratio|PainReform - P/S Multiple|Price-to-Revenue Coefficient Altamira Therapeutics CYTO|Lipella (LIPO) - Price-to-Revenue Ratio|Price-to-Sales Ratio OPTN (OptiNose Corp)|PIRS (Pieris Pharmaceuticals) - P/S Multiple|PROC: Market Capitalization-to-Revenue Ratio|P/S Multiple PTPI|P/S Multiple Acelyrin Inc. (SLRN)|Price-to-Revenue Ratio TFF Pharma TFFP
